Showing results (1861-1870 of 2,593) with videos related to

Sort By:
Pageof 260
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 5, 2003
In vivo recovery and safety of human factor VIII product AAFACT in patients with haemophilia AP J M Vossebeld, M H Tissing, H M Van Den Berg, et al.
The Lancet. Oncology|June 22, 2019
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind studyGeorgina V Long, Reinhard Dummer, Omid Hamid, et al.
The Lancet. Infectious Diseases|May 13, 2022
Doxycycline versus azithromycin for the treatment of anorectal Chlamydia trachomatis infection in women concurrent with vaginal infection (CHLAZIDOXY study): a multicentre, open-label, randomised, controlled, superiority trialOlivia Peuchant, Edouard Lhomme, Pervenche Martinet, et al.
Future Oncology (London, England)|September 17, 2020
Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumabMurtuza Bharmal, Sandra Nolte, Céleste Lebbé, et al.
European Journal of Cancer (Oxford, England : 1990)|October 27, 2017
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trialN Basset-Séguin, A Hauschild, R Kunstfeld, et al.
EFSA Journal. European Food Safety Authority|March 27, 2023
Safety evaluation of the food enzyme phytepsin from Cynara cardunculus L, Claude Lambré, José Manuel Barat Baviera, et al.
EFSA Journal. European Food Safety Authority|August 11, 2022
Safety evaluation of the food enzyme phosphoinositide phospholipase C from the genetically modified Bacillus licheniformis strain NZYM-DI, Claude Lambré, José Manuel Barat Baviera, et al.
The Lancet. Oncology|May 19, 2015
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trialNicole Basset-Seguin, Axel Hauschild, Jean-Jacques Grob, et al.
Frontiers in Pharmacology|December 19, 2019
Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method StudyEline van Overbeeke, Rosanne Janssens, Chiara Whichello, et al.
Blood|October 8, 2025
MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemiaDorien Pastoors, Marije Havermans, Roger Mulet-Lazaro, et al.
Pageof 260